Skip to content
Huberman LabHuberman Lab

Understanding & Healing the Mind | Dr. Karl Deisseroth

Karl Deisseroth, MD, PhD, is a clinical psychiatrist and scientist who directs a bioengineering research laboratory at Stanford University School of Medicine. His work aims to understand and develop treatments for disorders of the mind such as depression, attention deficit disorders (ADHD and ADD), autism, schizophrenia, anxiety, eating disorders, borderline personality disorder and obsessive-compulsive disorder (OCD). We discuss his experience treating patients and his laboratory’s mission to find and develop cures for mental diseases and tools for probing how the brain works. For an up-to-date list of our current sponsors, please visit our website: https://www.hubermanlab.com/sponsors. Previous sponsors mentioned in this podcast episode may no longer be affiliated with us. Dr. Karl Deisseroth Twitter: https://twitter.com/KarlDeisseroth New book: https://amzn.to/3diiKHG Lab Website: https://web.stanford.edu/group/dlab/ Social & Website Instagram: https://www.instagram.com/hubermanlab Twitter: https://twitter.com/hubermanlab Facebook: https://www.facebook.com/hubermanlab TikTok: https://www.tiktok.com/@hubermanlab LinkedIn: https://www.linkedin.com/in/andrew-huberman Website: https://hubermanlab.com Newsletter: https://hubermanlab.com/neural-network Timestamps: 00:00:00 Introduction 00:07:41 Using Language to Understand the Mind 00:12:19 Blood Tests For Mental Disease 00:13:38 The Largest Challenges Facing Treatment of Mental Health 00:20:21 Predicting Depression & Suicide 00:22:47 Drugs That Work for Brain Illness 00:27:01 What Would A Cure For the Broken Mind Look Like? 00:32:23 Channelopsins: Tools For Understanding & Treating the Mind 00:39:10 Curing Blindness with Channelopsins 00:41:58 Why Karl Became a Scientist 00:47:10 Vagus Nerve In Depression 00:54:12 Challenges To Overcome for Treating Mental Illness with Channelopsins 00:58:34 Using the Dialogue with Patients to Guide Treatment 01:00:52 How Our Eyes Reveal Our Mental Health 01:06:04 Controlling Structures Deep In the Brain 01:08:23 The Most Effective Drugs Often Have the Most Side Effects 01:09:50 Do Psychiatrists Take the Drugs They Prescribe? 01:14:15 Moving From Experimental Tools To Novel Treaments 01:16:00 Brain-Machine Interfaces & Neuralink 01:19:30 ADHD & Dr. Deissroth’s Approach To Focusing His Mind 01:26:36 How Dr. Deisseroth Balances A Career In Medicine, Science & Family 01:35:41 New Ways of Exploring Brains: CLARITY 01:38:49 What Is Special About the Human Brain? 01:46:03 Psychedelics 01:54:12 MDMA 01:57:15 Dr. Deisseroth’s New Book “Projections: A Story of Emotions” 01:59:42 Connecting with Dr. Deisseroth on Twitter The Huberman Lab Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user’s own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions.

Andrew HubermanhostKarl Deisserothguest
Jun 28, 20212h 2mWatch on YouTube ↗

CHAPTERS

  1. 0:00 – 30:00

    Introduction: Why Deisseroth and Why This Conversation

    Andrew Huberman introduces Dr. Karl Deisseroth as the first guest of the Huberman Lab podcast, outlining his dual role as psychiatrist and pioneering neuroscientist. He previews the themes: optogenetics, psychiatric disorders like depression and autism, psychedelic therapies, consciousness, and how Deisseroth manages an immense professional and personal workload. The segment also includes sponsor messages before the core discussion begins.

  2. 30:00 – 46:00

    Neurology vs. Psychiatry and the Problem of Measuring Feelings

    Deisseroth distinguishes neurology from psychiatry, emphasizing that neurology has visible lesions and tests, whereas psychiatry lacks objective physical markers. They explore how psychiatry is constrained by language, the difficulty of relying on patients’ words, and how clinicians parse real symptoms from colloquial labels like “depressed.” They also touch on comorbidities like Parkinson’s with depression, and whether we might eventually have quantitative tests for mental disorders.

  3. 46:00 – 1:00:00

    Diagnosing Emotions, Baselines, and Early Warning Signs

    The conversation turns to how psychiatrists get beyond vague labels to specific, operationalizable features of mood and motivation. Deisseroth explains how questions about hope, planning, sleep, and appetite map to diagnostic constructs like hopelessness or vegetative signs. They discuss the value and challenges of objective body-based measures (sleep logs, movement, voice changes) and how subtle behavioral shifts can signal approaching depressive episodes before patients notice.

  4. 1:00:00 – 1:16:00

    Are Psychiatric Treatments Any Good? Pills, Talk Therapy, and ECT

    Huberman asks whether psychiatry has any reliably effective treatments. Deisseroth affirms that both psychotherapy and medications can be highly effective in many cases, giving examples such as CBT for panic disorder and antipsychotics for schizophrenia. They dig into the trade-offs: powerful medications with serious side effects, and remarkably effective but mechanistically mysterious treatments like electroconvulsive therapy.

  5. 1:16:00 – 1:32:00

    Optogenetics: From Algae to Controlling Mammalian Brains

    Deisseroth recounts the origin story of channelrhodopsins from 19th-century observations of light-guided algae to modern genetic and optical manipulation in mammals. He explains how channelrhodopsins work at a biophysical level and how his lab solved practical challenges of gene delivery, expression, and light delivery. They discuss how optogenetics evolved from dish experiments to controlling mouse movement and eventually enabling partial vision in a blind human.

  6. 1:32:00 – 1:43:00

    Indirect Clinical Impact: Using Optogenetics to Design Smarter Treatments

    While partial vision restoration is dramatic, Deisseroth stresses that optogenetics’ greatest clinical impact will likely be indirect: using causal circuit mapping to inform all other treatments. They explore how understanding which cells and pathways underlie particular symptoms can guide the development or repurposing of drugs, refine brain stimulation targets, and make psychiatry more like cardiology in its mechanistic specificity.

  7. 1:43:00 – 2:08:00

    Vagus Nerve Stimulation: Crude Tool, Real Patients, Real-Time Tuning

    They drill into vagus nerve stimulation (VNS) as an example of both the promise and limitations of current neuromodulation. Deisseroth explains that VNS was chosen largely because the nerve is accessible and projects to brainstem nuclei linked to monoamine systems. He describes how he literally reprograms implant parameters via radio control in his clinic, balancing dose against side effects, and why optogenetic specificity could, in theory, vastly improve such interventions.

  8. 2:08:00 – 2:22:00

    Brain–Machine Interfaces, Deep Brain Stimulation, and Circuit-Conscious Psychiatry

    Huberman and Deisseroth discuss the broader landscape of brain–machine interfaces (BMI), including Neuralink and long-standing human work with stereo-EEG and deep brain stimulation. Deisseroth sees BMIs as valuable both for discovery and future clinical treatment—especially as closed-loop systems that detect pathological patterns and respond—with their specificity grounded in optogenetic research.

  9. 2:22:00 – 2:30:00

    ADHD, Tics, and the Role of Modern Environments

    ADHD is used as a case study of a diagnosis that straddles trait and environment. Deisseroth outlines the symptom clusters (hyperactive vs. inattentive), diagnostic criteria, and emerging EEG-based tools. Huberman shares personal history of childhood tics and relief from impact sports, raising the question of whether digital lifestyles and phones can create ADHD-like patterns or compulsions.

  10. 2:30:00 – 3:07:00

    Deisseroth’s Path: From Poetry to Psychiatry and Big Science

    Deisseroth traces his personal journey from being obsessed with poetry and language to pursuing neurosurgery, then being transformed by a required psychiatry rotation. He describes how the depth of suffering and mystery in psychiatric patients, combined with the intellectual fascination of altered realities, pulled him into psychiatry and research. He also talks about literary influences like Borges and his use of Spanish, and how those early loves shape his current work.

  11. 3:07:00 – 3:18:00

    CLARITY: Making Brains Transparent to See Their Wiring

    They shift to CLARITY and hydrogel tissue chemistry, another transformative technology from Deisseroth’s lab. He explains how embedding tissues in a polymer scaffold and washing out lipids makes entire brains optically transparent while preserving molecules of interest in place. This allows researchers to visualize neuronal architecture in 3D at cellular and subcellular resolution without slicing, opening new possibilities for understanding human and animal brain organization.

  12. 3:18:00 – 3:32:00

    Dissociation, Ketamine, and Cross-Species Circuit Mapping

    Deisseroth describes recent work on dissociation as an example of how optogenetics, human stereo-EEG, and pharmacology converge. Using dissociative anesthetics like ketamine in mice, they identified specific brain regions and activity patterns that correspond to being aware of stimuli but not caring about them. They then matched these patterns in a human epilepsy patient who reported dissociation before seizures, and causally reproduced dissociative-like states in mice by optogenetic replay.

  13. 3:32:00 – 3:51:00

    Psychedelics, MDMA, and How Altered States Might Heal

    They broaden from ketamine to psychedelics and MDMA as therapeutic tools. Deisseroth frames the cortex as a model-building system that normally filters out most speculative hypotheses before they reach consciousness. Psychedelics seem to relax that filter, letting unusual models into awareness, which may be harmful in extremes but potentially liberating for rigid, depressive thought patterns. MDMA’s unique combination of dopamine and serotonin flooding may teach new interpersonal possibilities, particularly in trauma therapy.

  14. 3:51:00 – 4:18:00

    Structuring a Life of Science, Clinics, Family, and Writing

    The final substantive segment turns inward to how Deisseroth manages his cognitive resources and time. He emphasizes structuring each day around at least an hour of uninterrupted, motionless thinking, often with an internal verbal monologue. During book-writing, he added midnight writing blocks and obsessively refined sentence rhythm and word choice. He sees focused introspection as both a trainable skill and a necessity for high-level intellectual work, while acknowledging that life must often be taken a day at a time.

  15. 4:18:00

    Closing Notes: Optimism, Projections, and Supporting Science

    Huberman and Deisseroth wrap up by reaffirming optimism about the trajectory of psychiatry given current tools and discoveries. Huberman endorses *Projections* as both scientifically rigorous and beautifully written, and they briefly mention ways for listeners to follow Deisseroth or support the podcast. Huberman reiterates his mission of sharing science-based tools with the public at zero cost.

Get more out of YouTube videos.

High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.

Add to Chrome